Circulogene Theranostics Names James A. Posey III, M.D., As Chief Medical Advisor

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Circulogene Theranostics, the only biotechnology company able to enrich circulating cell-free DNA (cfDNA) from a single blood drop for patient-specific monitoring of cancer, has named medical oncologist James A. Posey III, M.D., as Chief Medical Advisor.

In his new role, Dr. Posey will help educate other oncologists about the efficacy and availability of Circulogene's cfDNA liquid biopsy products and will be responsible for further validation of the company's proprietary technology.

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”